Pieris Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Note 5 - Cash, Cash Equivalents and Investments (Tables)

Note 5 - Cash, Cash Equivalents and Investments (Tables)

9 Months Ended

Sep. 30, 2022

Notes Tables

Cash, Cash Equivalents and Investments [Table Text Block]

		*Total*				*Quoted prices in active markets (Level 1)*				*Significant other observable inputs (Level 2)*				*Significant unobservable inputs (Level 3)*
September 30, 2022
Money market funds, included in cash equivalents		$	25,183			$	25,183			$	—			$	—
Investments - US treasuries			2,674				2,674				—				—
Investments - Foreign treasuries			894				894				—				—
Investments - Asset-backed securities			497				—				497				—
Investments - Corporate bonds			17,335				—				17,335				—
Total		$	46,583			$	28,751			$	17,832			$	—

		Total				Quoted prices in active markets (Level 1)				Significant other observable inputs (Level 2)				Significant unobservable inputs (Level 3)
December 31, 2021
Money market funds, included in cash equivalents		$	56,885			$	56,885			$	—			$	—
Total		$	56,885			$	56,885			$	—			$	—

Debt Securities, Available-for-Sale [Table Text Block]

		*Contractual maturity*
		*(in days)*			*Amortized Cost*				*Unrealized gains*				*Unrealized losses*				*Fair Value*
Investments
US treasuries		6-153			$	2,676			$	—			$	(2	)		$	2,674
Foreign treasuries		166				898				—				(4	)			894
Asset-backed securities		107				500				—				(3	)			497
Corporate bonds		1-251				17,244				126				(35	)			17,335
Total					$	21,318			$	126			$	(44	)		$	21,400